<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01955642</url>
  </required_header>
  <id_info>
    <org_study_id>1208094</org_study_id>
    <secondary_id>2013-000313-20</secondary_id>
    <nct_id>NCT01955642</nct_id>
  </id_info>
  <brief_title>Evaluation of the Biological Response to Clopidogrel in Patients With Ischemic Stroke</brief_title>
  <acronym>AAPIX</acronym>
  <official_title>Evaluation of the Biological Response to Clopidogrel in Patients With Ischemic Stroke : Role of Platelet alpha2-adrenergic Receptors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Groupe de Recherche sur la Thrombose</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ischemic stroke (AIC) is the leading cause of non-traumatic disability in adults, the second&#xD;
      leading cause of dementia and the third leading cause of death in France.&#xD;
&#xD;
      Clopidogrel is one of the recommended first line in the secondary prevention of AIC non&#xD;
      cardioembolic origin. However recurrences occur in approximately 9% of patients receiving&#xD;
      clopidogrel. Some studies in patients with coronary artery disease have made the connection&#xD;
      between these treatment failures and non-biological response to clopidogrel. This&#xD;
      non-biological response is found for approximately 30% to 50% of patients. Several mechanisms&#xD;
      may explain this non-response. The most accepted mechanism is pharmacokinetic. Indeed,&#xD;
      clopidogrel is a prodrug that requires intestinal absorption by P-glycoprotein (PGP) and a&#xD;
      transformation by hepatic cytochrome into active metabolites. The genetic polymorphism of&#xD;
      proteins involved in these two steps explain the low plasma concentration of active&#xD;
      metabolites and thus the low efficacy of clopidogrel in some patients.&#xD;
&#xD;
      A new pharmacodynamic hypothesis suggests the involvement of platelet alpha 2-adrenergic&#xD;
      receptors. The activation of these receptors potentiates signaling pathway P2Y12 receptor&#xD;
      (channel inhibited by clopidogrel) and helps reduce platelet aggregation inhibiting response&#xD;
      to clopidogrel.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Interest in the biological response to clopidogrel in the AIC is innovative because few data&#xD;
      are available in this area. In addition to testing a new pharmacodynamic hypothesis, we also&#xD;
      wish to study and compare other measures of platelet function methods in order to be able to&#xD;
      use commonly in treatment decisions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>adrenergic component of the platelet response</measure>
    <time_frame>5 days after taking clopidogrel</time_frame>
    <description>adrenergic component of the platelet response is estimated by the difference between the maximum percentage of platelet aggregation by light transmission aggregometry (LTA) with the addition of ADP(adenosine diphosphate) + ADP versus selective agonist (epinephrine)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>VASP-CMF</measure>
    <time_frame>After 5 days taking clopidogrel</time_frame>
    <description>Platelet reactivity index (PRI) by VASP CMF (flow cytometry) method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ELISA VASP</measure>
    <time_frame>After 5 days taking clopidogrel</time_frame>
    <description>Platelet reactivity index (PRI-ELISA) using ELISA VASP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>active metabolite of clopidogrel</measure>
    <time_frame>After 5 days taking clopidogrel</time_frame>
    <description>Rate of residual plasma active metabolite of clopidogrel (R-130964)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genotyping of MDR-1 and P450 2C19</measure>
    <time_frame>After 5 days taking clopidogrel</time_frame>
    <description>Genotyping of MDR-1 and P450 2C19</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">91</enrollment>
  <condition>Brain Ischemia</condition>
  <condition>Ischemic Attack</condition>
  <arm_group>
    <arm_group_label>AVC</arm_group_label>
    <description>Patients with non-cardioembolic AIC requiring initiation of treatment with clopidogrel as usual indications</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>75 mg milligrams per days of PLAVIX</description>
    <arm_group_label>AVC</arm_group_label>
    <other_name>PLAVIX(R)</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood DNA&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with non-cardioembolic AIC requiring initiation of treatment with clopidogrel as&#xD;
        usual indications&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Consent signed&#xD;
&#xD;
          -  Patients with non-cardioembolic AIC requiring initiation of treatment with clopidogrel&#xD;
             as usual indications&#xD;
&#xD;
          -  normal standard biological tests&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Need to continue aspirin therapy&#xD;
&#xD;
          -  Patients with a recurrence of clopidogrel AIC&#xD;
&#xD;
          -  Patient already tacking clopidogrel&#xD;
&#xD;
          -  Drugs interfering with the adrenergic system alpha blockers, alpha 2 receptor agonists&#xD;
             (alpha-methyldopa) and alpha2 receptor inhibitors (Mianserin, Mirtazapine, yohimbine)&#xD;
&#xD;
          -  Contra indication of clopidogrel and / or any of its excipients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerome VARVAT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Saint-Etienne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Saint-Etienne</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>September 27, 2013</study_first_submitted>
  <study_first_submitted_qc>October 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2013</study_first_posted>
  <last_update_submitted>December 30, 2015</last_update_submitted>
  <last_update_submitted_qc>December 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clopidogrel</keyword>
  <keyword>Brain Ischemia</keyword>
  <keyword>Ischemic attack</keyword>
  <keyword>Biological response to clopidogrel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

